Table 3.
Antibiotic groups used during the period of 2006–2015 and 2017 (DDD/100 BD and DDD/100 inpatients).
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DDD/100 BD: | |||||||||||
| Aminoglycosides (J01G) | 3.9 | 4.0 | 3.3 | 3.3 | 2.5 | 3.3 | 3.0 | 3.6 | 3.5 | 2.3 | 2.3 |
| β-lactam AB, penicillins (J01C) | 23.0 | 24.2 | 19.7 | 20.4 | 22.0 | 22.0 | 19.8 | 19.7 | 14.2 | 18.7 | 21.2 |
| Macrolides and lincosamides (J01F) | 1.3 | 2.1 | 1.2 | 1.0 | 1.4 | 1.9 | 3.4 | 3.5 | 2.6 | 8.1 | 4.9 |
| Other β-lactam AB (J01D) | 6.8 | 10.3 | 9.2 | 8.3 | 9.4 | 11.2 | 12.2 | 16.4 | 16.7 | 15.7 | 16.8 |
| Quinolones (J01M) | 0.7 | 1.3 | 0.5 | 0.3 | 0.5 | 1.8 | 0.6 | 0.9 | 1.9 | 1.4 | 1.0 |
| Tetracyclines (J01A) | 0.2 | 0.5 | 0.6 | 0.4 | 0.5 | 0.6 | 0.4 | 0.2 | 0.4 | 0.3 | 0.2 |
| Other AB (J01X) | 1.9 | 2.7 | 1.1 | 2.2 | 2.3 | 2.4 | 3.3 | 4.0 | 3.4 | 4.3 | 5.2 |
| Sulfonamides and trimethoprim (J01E) | 1.6 | 1.6 | 2.0 | 2.1 | 1.8 | 0.5 | 0.4 | 0.8 | 3.2 | 2.4 | 2.7 |
| DDD/100 inpatients: | |||||||||||
| Aminoglycosides (J01G) | 22 | 22 | 19 | 18 | 18 | 16 | 13 | 15 | 18 | 12 | 11 |
| β-lactam AB, penicillins (J01C) | 131 | 136 | 112 | 107 | 111 | 90 | 88 | 82 | 74 | 57 | 104 |
| Macrolides and lincosamides (J01F) | 7 | 12 | 7 | 5 | 7 | 9 | 15 | 15 | 13 | 16 | 24 |
| Other β-lactam AB (J01D) | 39 | 58 | 52 | 43 | 47 | 53 | 54 | 69 | 85 | 83 | 82 |
| Quinolones (J01M) | 4 | 7 | 3 | 2 | 3 | 9 | 3 | 4 | 10 | 7 | 5 |
| Tetracyclines (J01A) | 1 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | 2 | 0.3 | 1 |
| Other AB (J01X) | 11 | 15 | 6 | 12 | 12 | 11 | 15 | 17 | 18 | 22 | 25 |
| Sulfonamides and trimethoprim (J01E) | 9 | 9 | 11 | 11 | 9 | 2 | 2 | 3 | 17 | 12 | 13 |